Reviewer's report

Title: Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients

Version:2 Date: 3 October 2014

Reviewer: marinella tricarico

Reviewer's report:

Pedersen et al performed an intering study to identify new markers of CVD disease in type 2 diabetes mellitus patients.

Minor essential revisions:
1) Why do you have chosen type 2 diabetic patients not in therapy?
2) The use of fecal test on plasma for detection of Calprotectin has already been validated? What is the cost of this test compared to conventional markers of miocardial necrosis for example?
3) Therefore, we can define Calprotectin as a new validated marker of chronic inflammation rather than of cardiovascular disease or glucose homeostasis?
4) So, in non diabetic patients with hyperglycemia for manifestation of inflammation, for example in sepsis, we expect high levels of Calprotectin even if insulin resistance is absent?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests